Pernix Reinvention Comes Down To Execution
This article was originally published in The Pink Sheet Daily
Executive Summary
Pernix has a new management team and a budding portfolio of CNS drugs, gained via M&A. Now the company needs to prove it can grow brands that compete in highly genericized markets and drive sustainable growth.